What is HC Wainwright’s Estimate for Alkermes Q2 Earnings?

Alkermes plc (NASDAQ:ALKS) – Stock analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Alkermes in a research report issued to clients and investors on Wednesday, May 6th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.08) for the quarter, up from their previous estimate of ($0.26). HC Wainwright currently has a “Neutral” rating and a $43.00 target price on the stock. The consensus estimate for Alkermes’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Alkermes’ Q3 2026 earnings at $0.03 EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.52 EPS.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Saturday, February 14th. The company reported $0.29 earnings per share (EPS) for the quarter. The business had revenue of $384.55 million during the quarter. Alkermes had a return on equity of 9.26% and a net margin of 9.78%.

ALKS has been the topic of a number of other research reports. Truist Financial upgraded Alkermes to a “strong-buy” rating in a report on Wednesday, March 25th. Robert W. Baird boosted their target price on Alkermes from $45.00 to $48.00 and gave the stock an “outperform” rating in a research note on Wednesday. Wells Fargo & Company upped their price target on Alkermes from $43.00 to $44.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Bank of America increased their price target on shares of Alkermes from $34.00 to $36.00 and gave the company a “neutral” rating in a research note on Thursday, April 9th. Finally, Weiss Ratings cut shares of Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.40.

Alkermes Stock Performance

Shares of ALKS opened at $38.91 on Thursday. The stock has a market capitalization of $6.49 billion, a PE ratio of 43.23 and a beta of 0.31. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.70 and a current ratio of 2.27. The stock has a 50-day simple moving average of $32.14 and a 200-day simple moving average of $31.21. Alkermes has a 1 year low of $25.17 and a 1 year high of $39.56.

Insider Buying and Selling

In related news, EVP David Joseph Gaffin sold 2,034 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.20, for a total transaction of $67,528.80. Following the transaction, the executive vice president owned 231,558 shares in the company, valued at $7,687,725.60. This trade represents a 0.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Todd Nichols sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the transaction, the senior vice president owned 109,769 shares in the company, valued at $3,293,070. This represents a 5.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 39,102 shares of company stock worth $1,265,090 in the last quarter. 4.59% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Assetmark Inc. grew its stake in shares of Alkermes by 933.8% in the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 747 shares during the last quarter. Cullen Frost Bankers Inc. purchased a new position in shares of Alkermes in the 4th quarter valued at approximately $28,000. Johnson Financial Group Inc. purchased a new position in shares of Alkermes in the 3rd quarter valued at approximately $31,000. UMB Bank n.a. grew its stake in shares of Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after purchasing an additional 446 shares during the last quarter. Finally, Salomon & Ludwin LLC grew its stake in shares of Alkermes by 115.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after purchasing an additional 667 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Robert W. Baird raised its price target on Alkermes to $48 from $45 and kept an outperform rating, signaling greater confidence in the stock’s upside after the company’s recent earnings and pipeline momentum. Benzinga article
• Positive Sentiment: HC Wainwright lifted its near-term earnings outlook for Alkermes, including higher Q2 2026, Q3 2026, and FY2026 EPS estimates, which suggests analysts see better profitability than before. HC Wainwright estimate updates
• Positive Sentiment: Investor sentiment also got a boost from positive topline results for LUMRYZ in the REVITALYZ phase 3 sleep-disorder study, which supports Alkermes’ growth prospects in its neuroscience portfolio. Benzinga clinical update
• Neutral Sentiment: HC Wainwright kept a Neutral rating and $43 price target, which is constructive but not a strong bullish call. HC Wainwright report
• Neutral Sentiment: Some longer-term earnings forecasts were reduced for FY2027 through FY2030, tempering the optimism around Alkermes’ far-out profitability trajectory. HC Wainwright report

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.